Table of Contents
<< Previous Issue | Sept 2019 (Vol: 2019, Issue: 9) | Next Issue >> |
- Section: Licensing
-
GSK Exercises Option for Ionis’ Hepatitis B Programmes
-
Celgene Fortifies Immuno-oncology Presence with Immatics Alliance
-
Astellas Licenses RIKEN’s aAVC Cell Therapy Technology for US$9.4 M Upfront
- Section: Mergers & Acquisitions
-
Amgen to Acquire Celgene’s Otezla® for US$13.4 B
-
Vertex Branches into Diabetes Field with Semma Therapeutics Acquisition
-
Lundbeck Expands CNS Franchise with US$2 B Alder Acquisition
- Section: Opinion & Analysis
-
IQVIA Pharma Deals Half-Year Review of 2019